01—History
Free Cash Flow History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.
- $748.7M
4 older moves run past ±150% (largest −2404.5%); point at, tap or drag across the bars to read one.
02—Ledger
Free Cash Flow, period by period
| Period | Scale | Value | Change | Source |
|---|---|---|---|---|
| FY2025 | $748.7M | +34.4% | 10-K | |
| FY2024 | $557.2M | +54.1% | 10-K | |
| FY2023 | $361.6M | +12.0% | 10-K | |
| FY2022 | $322.9M | +38.5% | 10-K | |
| FY2021 | $233.1M | +7.1% | 10-K | |
| FY2020 | $217.6M | +64.5% | 10-K | |
| FY2019 | $132.3M | +72.7% | 10-K | |
| FY2018 | $76.6M | +175.6% | 10-K | |
| FY2017 | −$101.3M | +8.2% | 10-K | |
| FY2016 | −$110.3M | −176.2% | 10-K | |
| FY2015 | −$39.9M | +18.1% | 10-K | |
| FY2014 | −$48.8M | −61.7% | 10-K | |
| FY2013 | −$30.2M | +16.9% | 10-K | |
| FY2012 | −$36.3M | −2404.5% | 10-K | |
| FY2011 | −$1.4M | −102.9% | 10-K | |
| FY2010 | $49.6M | +193.4% | 10-K | |
| FY2009 | −$53.1M | — | 10-K |
03—Questions
What is Neurocrine Biosciences's current free cash flow?
Neurocrine Biosciences (NBIX) annual free cash flow for 2025 was $748.7M, a 34.37% increase from 2024. Neurocrine Biosciences free cash flow for the quarter ending September 30, 2026 was $383.6M.
What was Neurocrine Biosciences's free cash flow in 2024?
Neurocrine Biosciences annual free cash flow for 2024 was $557.2M, a 54.09% increase from 2023.
What was Neurocrine Biosciences's free cash flow in 2023?
Neurocrine Biosciences annual free cash flow for 2023 was $361.6M, a 11.99% increase from 2022.
What is Neurocrine Biosciences's 5-year free cash flow CAGR?
Neurocrine Biosciences free cash flow grew at a compound annual growth rate (CAGR) of 28.04% from FY2020 to FY2025, going from $217.6M to $748.7M over 5 years.
- Company
- Neurocrine Biosciences
- Ticker
- NBIX
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)